Exploring the Potential Mechanisms of Moringa oleifera and Rice Bran in Iron Deficiency Anaemia: A Drug-Likeness and Network Pharmacology Approach

Quercetin — a plant compound found in Moringa oleifera — shows far more promise than γ-oryzanol from rice bran when it comes to computationally predicted interactions with iron deficiency anaemia (IDA) pathways, according to this network pharmacology study. IDA is the world's most common nutritional disorder, driven not just by low iron intake but by inflammation and a hormone called hepcidin that blocks iron release from cells. Rather than running laboratory experiments, the researchers used computer-based tools to ask: could these two bioactive compounds interact with the biological targets involved in IDA? They assessed whether each compound had drug-like properties suitable for oral use, predicted which human proteins each compound might bind to, and then mapped those proteins onto known disease pathways. Quercetin passed standard drug-likeness criteria and was linked to 380 predicted IDA-related targets, including proteins on the hepcidin–ferroportin axis — the central switch controlling how much iron enters the bloodstream. γ-Oryzanol, by contrast, failed two key drug-likeness thresholds (its molecular weight exceeds 500 and its fat-solubility score exceeds 5), raising questions about how well it would be absorbed orally. It was also linked to only three predicted targets, with its network centred mainly on the inflammatory protein IL-6. The authors are careful to stress that these are hypothesis-generating findings only — no cells, animals, or humans were studied. The results point to quercetin as the more tractable candidate for follow-up IDA research, while γ-oryzanol's limitations suggest it would need reformulation or alternative delivery before being seriously considered as an oral intervention.